J Bacteriol Virol.  2018 Jun;48(2):67-71. 10.4167/jbv.2018.48.2.67.

NLRC3 Attenuates Colon Cancer by Down-Regulating PI3K-mTOR Signaling

• Ali I
• Koh YS

• KMID: 2414857
• DOI: http://doi.org/10.4167/jbv.2018.48.2.67

Abstract

The nucleotide-binding oligomerization domain-like receptors (NOD-like receptors, NLRs) are intracellular sensors. Most of them positively affect inflammatory responses, particularly the inflammasome forming NLRs. On the other hand, several studies on gene-deficient mice have revealed that several NLRs negatively influence innate immune responses. Some recent studies have identified a novel sub-group of non-inflammasome forming NLRs that negatively influence different pathways related to inflammation and carcinogenesis. Cytosolic pattern recognition receptor NRLC3 is a negative regulator of innate immune response. In this review we will discuss finding related with NLRC3 and its mechanism by which it alter cancer pathogenesis. Recently, it has been found that mice deficient in Nlrc3 are hyper-susceptible to colitis and colitis-associated colon carcinogenesis. Oncogenic inhibitory effect of NLRC3 is more dominant in epithelial compartment than hematopoietic compartment. It down regulates mTOR signaling and reduce cell proliferation. NLRC3 interact with PI3Ks and suppress activation of PI3K dependent kinase AKT. Understanding the role of NLRC3 in cancer may facilitate the recognition of new therapeutic strategies.

Keyword

NLRC3; mTOR; Colon cancer

MeSH Terms

Animals
Carcinogenesis
Cell Proliferation
Colitis
Colon*
Colonic Neoplasms*
Cytosol
Hand
Immunity, Innate
Inflammasomes
Inflammation
Mice
Phosphotransferases
Inflammasomes
Phosphotransferases

Reference

1. Liu R, Truax AD, Chen L, Hu P, Li Z, Chen J, et al. Expression profile of innate immune receptors, NLRs and AIM2, in human colorectal cancer: correlation with cancer stages and inflammasome components. Oncotarget. 2015; 6:33456–33469.

2. Dupaul-Chicoine J, Arabzadeh A, Dagenais M, Douglas T, Champagne C, Morizot A, et al. The NLRP3 inflammasome suppresses colorectal cancer metastatic growth in the liver by promoting natural killer cell tumoricidal Activity. Immunity. 2015; 43:751–763.

3. Lechtenberg BC, Mace PD, Riedl SJ. Structural mechanism in NLR inflammasome signaling. Curr Opin Struct Biol. 2014; 29:17–25.

4. Mótyán JA, Bagossi P, Benkö S, Tözsér JA. Molecular model of the full-length NOD-like receptor family CARD domain containing 5(NLRC5) protein. BMC Bioinformatics. 2013; 14:275.

5. GültekinY , Eren E, Özören N. Overexpressed NLRC3 acts as an anti-inflammatory cytosolic protein. J Innate Immun. 2015; 7:25–36.

6. Allen IC. Non-inflammasome forming NLRs in inflammation and tumorigenesis. Front Immunol. 2014; 5:169.

7. Zhang L, Mo J, Swanson KV, Wen H, Petrucelli A, Gregory SM, et al. NLRC3, a member of the NLR family of proteins, is a negative regulator of innate immune signaling induced by the DNA sensor STING. Immunity. 2014; 40:329–341.

8. Karki R, Man SM, Malireddi RK, Kesavardhana S, Zhu Q, Burton AR, et al. NLRC3 is an inhibitory sensor of PI3K-mTOR pathways in cancer. Nature. 2016; 540:583–587.

9. Schneider M, Zimmermann AG, Roberts RA, Zhang L, Swanson KV, Wen H, et al. The innate immune sensor NLRC3 attenuates Toll-like receptor signaling via modification of the signaling adaptor TRAF6 and transcription factor NF-κB. Nat Immunol. 2012; 13:823–831.

10. Huber S, Gagliani N, Zenewicz LA, Huber FJ, Bosurgi L, Hu B, et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature. 2012; 491:259–263.

11. Tattoli I, Killackey SA, Foerster EG, Molinaro R, Maisonneuve C, Rahman MA, et al. NLRX1 acts as an epithelial-intrinsic tumor suppressor through the modulation of TNF-mediated proliferation. Cell Rep. 2016; 14:2576–2586.

12. Guo Y, Yu T, Yang J, Zhang T, Zhou Y, He F, et al. Metformin inhibits salivary adenocarcinoma growth through cell cycle arrest and apoptosis. Am J Cancer Res. 2015; 5:3600–3611.

13. Li X, Wu C, Chen N, Gu H, Yen A, Cao L, et al. PI3K/AKT/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget. 2016; 7:33440–33450.

14. Koblansky AA, Truax AD, Liu R, Montgomery SA, Ding S, Wilson JE, et al. The innate immune receptor NLRX1 Functions as a tumor suppressor by reducing colon tumorigenesis and key tumor-promoting signals. Cell Rep. 2016; 14:2562–2575.